These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3022510)

  • 1. Clinical pharmacology of the angiotensin converting enzyme inhibitor, enalapril.
    Brunner HR; Nussberger J; Waeber B
    Acta Cardiol; 1986; 41(5):341-50. PubMed ID: 3022510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enalapril: a new angiotensin converting enzyme inhibitor.
    Cleary JD; Taylor JW
    Drug Intell Clin Pharm; 1986 Mar; 20(3):177-86. PubMed ID: 3007062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical pharmacology of enalapril.
    Gomez HJ; Cirillo VJ; Jones KH
    J Hypertens Suppl; 1983 Oct; 1(1):65-70. PubMed ID: 6100610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Vlasses PH; Larijani GE; Conner DP; Ferguson RK
    Clin Pharm; 1985; 4(1):27-40. PubMed ID: 2982541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enalapril: a new angiotensin-converting enzyme inhibitor.
    McRaith J; Fitz A
    Iowa Med; 1986 Oct; 76(10):482, 484, 486-8. PubMed ID: 3023256
    [No Abstract]   [Full Text] [Related]  

  • 7. Enalapril: a review of human pharmacology.
    Gomez HJ; Cirillo VJ; Irvin JD
    Drugs; 1985; 30 Suppl 1():13-24. PubMed ID: 2994984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enalapril: a long-acting angiotensin-converting enzyme inhibitor.
    Borek M; Charlap S; Frishman W
    Pharmacotherapy; 1987; 7(5):133-48. PubMed ID: 2829141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
    Todd PA; Heel RC
    Drugs; 1986 Mar; 31(3):198-248. PubMed ID: 3011386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of enalapril. Summing up the evidence.
    Dollery CT
    J Hypertens Suppl; 1983 Oct; 1(1):155-7. PubMed ID: 6100605
    [No Abstract]   [Full Text] [Related]  

  • 11. Symposium: Converting enzyme inhibition. New trends in the treatment of hypertension and congestive heart failure. Brussels, Belgium, June 21, 1985.
    Acta Cardiol; 1986; 41(5):329-96. PubMed ID: 3022508
    [No Abstract]   [Full Text] [Related]  

  • 12. Lisinopril: a new ACE inhibitor for the treatment of hypertension and congestive heart failure.
    Chodoff L
    Mt Sinai J Med; 1990 May; 57(3):169-71. PubMed ID: 2164644
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical pharmacology of enalapril].
    Giudicelli JF
    Presse Med; 1985 Dec; 14(44):2209-11. PubMed ID: 3003727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
    Kitaoka H; Takata J; Hitomi N; Furuno T; Seo H; Chikamori T; Doi YL
    Am J Cardiol; 2000 Mar; 85(5):658-60, A10. PubMed ID: 11078286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with lisinopril in congestive heart failure. Focus on the older patient.
    Giles TD
    Drugs; 1990; 39 Suppl 2():17-22. PubMed ID: 2160883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The angiotensin converting enzyme inhibitor enalapril and its effects on renal function.
    de Zeeuw D; Navis GJ; Donker AJ; de Jong PE
    J Hypertens Suppl; 1983 Oct; 1(1):93-7. PubMed ID: 6100614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new angiotensin-converting enzyme inhibitor: treatment of hypertension and congestive heart failure. Proceedings of an international symposium on enalapril, sponsored by Merck Sharp & Dohme International, São Paulo, Brazil, November 10, 1984.
    Drugs; 1985; 30 Suppl 1():1-96. PubMed ID: 2994983
    [No Abstract]   [Full Text] [Related]  

  • 18. A three year clinical review of the impact of angiotensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians.
    Adewole AD; Ikem RT; Adigun AQ; Akintomide AO; Balogun MO; Ajayi AA
    Cent Afr J Med; 1996 Aug; 42(8):253-5. PubMed ID: 8990572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of enalapril.
    Abrams WB; Davies RO; Gomez HJ
    J Hypertens Suppl; 1984 Dec; 2(2):S31-6. PubMed ID: 6100874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.